<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727699</url>
  </required_header>
  <id_info>
    <org_study_id>ACW0002</org_study_id>
    <nct_id>NCT02727699</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)</brief_title>
  <acronym>XanADu</acronym>
  <official_title>XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actinogen Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actinogen Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety,&#xD;
      tolerability and efficacy of Xanamem™ in subjects with mild dementia due to Alzheimer's&#xD;
      Disease. Subjects will be randomized to receive either 10mg once daily Xanamem™ or Placebo at&#xD;
      a 1:1 ratio in a double-blinded fashion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled&#xD;
      proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem™ once&#xD;
      daily in adult subjects with mild dementia due to AD.&#xD;
&#xD;
      Based on Xanamem™'s mode of action on hippocampal function, amnestic symptoms may respond&#xD;
      best, thus favouring the inclusion of mild dementia due to AD, with given evidence of disease&#xD;
      progression. Subjects will be treated in a double-blind fashion, where both the investigators&#xD;
      and subjects will be unaware of the treatment assignments, to minimise any subjective or&#xD;
      unrecognised bias carried by the investigators and subjects. Placebo will be used as the&#xD;
      comparator in this study.&#xD;
&#xD;
      It is planned to randomise approximately 174 subjects at approximately 25 study sites in&#xD;
      three countries (Australia, United Kingdom, and United States), with the aim to enrol 7 to 10&#xD;
      subjects at each study site. Subject enrolment will be competitive but a cap of 20 subjects&#xD;
      per study site is to be established to avoid any side effects. In case the sample composition&#xD;
      at one study site is creating concerns, an enrolment stop can also occur at fewer than 20&#xD;
      subjects.&#xD;
&#xD;
      At study end, a total of 185 subjects were randomised into this study and received active&#xD;
      treatment.&#xD;
&#xD;
      The data safety monitoring board (DSMB) will periodically meet for the review of accumulating&#xD;
      safety study data and will also be involved in the interim analysis.&#xD;
&#xD;
      At the Baseline visit (Week 0), eligible subjects will be randomised on a 1:1 ratio to&#xD;
      receive either Xanamem™ administered orally once daily (QD) for the treatment group or&#xD;
      matching placebo for the placebo group. Subjects will return to the study site for visits at&#xD;
      Week 4 and Week 8, End of Treatment (Week 12) and Follow-up (4 weeks post last dose of study&#xD;
      drug) visits, at which study assessments will be performed.&#xD;
&#xD;
      Ad hoc telephone contact may also occur at any other time-point throughout the study, if&#xD;
      deemed necessary by the investigator/study nurse, or if the subject wishes to report an&#xD;
      Adverse Event (AE)&#xD;
&#xD;
      Subjects will be interviewed and examined at the study site at each visit and will complete a&#xD;
      variety of questionnaires and routine safety evaluations.&#xD;
&#xD;
      Optional Pharmacodynamic (PD) sampling will be performed at specific visits. Subjects who do&#xD;
      not provide consent for this optional sub-study will still be eligible for the main study.&#xD;
&#xD;
      The overall study duration for an individual subject will be 17 to 20 weeks, including a&#xD;
      screening period of one to 4 weeks, a double-blind treatment period of 12 weeks, and a&#xD;
      follow-up period of 4 weeks. The total duration of the study is expected to be 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog v14</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scales - Cognitive Subscale Score, version 14 (ADAS-Cog v14) Total scores of ADAS Cog 14 range from 0 to 90, with higher scores indicating greater disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AD COMposite Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in AD COMposite Scores (ADCOMs- ADCOMs, composite score is derived from a weighted linear combination of items from commonly used outcome scales Cognitive Subscale Version 14 [ADAS-Cog v14], Clinical Dementia Rating Scale - Sum of Boxes [CDR-SOB], and Mini-Mental Status Examination [MMSE]. Th ADCOMs range: 0 - 1.97, whereas a lover score is interpreted as a better result.&#xD;
Included scales:&#xD;
ADAS-Cog v14 (range: 0-90): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
CDR-SOB (range: 0-18): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
MMSE (range: 0-30): A higher score is indicative of better cognition, a lower score indicates higher cognitive impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAVLT</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Rey Auditory Verbal Learning Test (RAVLT) RAVLT will be administered using five trials, with individual scores from 0-15. The total score is the combined score of all five trials, ranging from 0 to 75, whereas a lower score is considered a worse outcome and a higher score a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR-SOB</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB) The CDR is obtained through semi-structured interviews of patients and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.&#xD;
Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment.&#xD;
The CDR-SOB is based on summing each of the domain box scores, with scores ranging from 0-18, whereas lower scores represent better outcomes and higher scores worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Mini-Mental Status Examination (MMSE) MMSE total score (0 - 30) is a sum of all 30 point questionnaire of MMSE. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPI (Neuropsychiatric Inventory)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Neuropsychiatric Inventory (NPI) The NPI includes questions to ten behavioural and two neurodegenerative domains.&#xD;
Raters recorded neuropsychiatric symptoms using a 1-4 scale for frequency and a 1-3 scale for severity for each item in the instrument, with the score for each domain being: domain score = frequency x severity.&#xD;
The total score is calculated by adding the scores of the first 10 domain scores.&#xD;
The two neurodegenerative items are not included in the NPI total score as they form part of the depression syndrome in some patients and were specifically excluded from the dysphoria subscale of the NPI in order to allow that subscale to focus on mood symptoms.&#xD;
The total NPI-score minimum is 0 and the maximum 144. A lower score is considered a better outcome, a higher score a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTB - Executive Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Neuropsychological Test Batteries (NTB) - Executive Domains: Controlled Oral Word Association - Test (COWAT) and Total Correct Response (CFT) Total NTB score is the sum of COWAT and CFT. During the COWAT test, the subject is asked to mention as many words as possible beginning with different letters (F, A, S) within 1 minute each. The number of words for each letter is recorded, the score is the sum of all words. There is no minimum or maximum score, whereas more words indicate a better outcome.&#xD;
During the CFT test, the subject is given 1 minute to produce as many unique words as possible within a semantic category. The subject's score is the number of unique correct words.&#xD;
There is no minimum or maximum score whereas a score of under 14 is interpreted as concerning regarding cognition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pregnancy Test</measure>
    <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
    <description>Women of childbearing potential only. Serum pregnancy test at screening and a urine pregnancy test at all subsequent clinic visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Testosterone</measure>
    <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
    <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Androstenedione</measure>
    <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
    <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Dehydroepiandrosterone Sulfate (DHEAS)</measure>
    <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
    <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Adrenocorticotropic Hormone (ACTH)</measure>
    <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
    <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Pharmacokinetics (PK), Including Analysis of Cortisol Levels</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12 and Unscheduled Safety Visit</time_frame>
    <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
  </other_outcome>
  <other_outcome>
    <measure>NTSS-6</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc and Unscheduled Safety Visit</time_frame>
    <description>Change in Neuropathy Total Symptom Score (NTSS-6)</description>
  </other_outcome>
  <other_outcome>
    <measure>NFM</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
    <description>Change in Nerve Function Monitoring (NFM)</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Unscheduled Safety Visit</time_frame>
    <description>Change in Vital Signs (including Heart Rate, Blood Pressure, Body Weight, BMI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolic Function</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in Metabolic Function Test Results of Lipids, Glucose, Hemoglobin A1c (HbA1c)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Safety Laboratory Values</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
    <description>Change in Clinical Safety Laboratory Values (biochemistry, hematology, urine examination)</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc</time_frame>
    <description>Incidence of Adverse Events (AEs)</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
    <description>Change in Electrocardiogram (ECG) Values</description>
  </other_outcome>
  <other_outcome>
    <measure>CSSRS</measure>
    <time_frame>Screening, Week 4, Week 8, Week 12, Week 16</time_frame>
    <description>Change in Scores of Columbia Suicide Severity Rating Scale (CSSRS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Dementia, Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>Xanamem™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Xanamem™ capsules 10mg, to be administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xanamem™</intervention_name>
    <description>Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
    <arm_group_label>Xanamem™</arm_group_label>
    <other_name>UE2343</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Xanamem™)</intervention_name>
    <description>Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged 50 years or older at the time of informed consent.&#xD;
&#xD;
          2. Female Subjects:&#xD;
&#xD;
               1. Post menopausal women, defined as no menses for 12 months without an alternative&#xD;
                  medical cause. If there is any concern about the menopausal status of a&#xD;
                  prospective female subject, a follicle stimulating hormone test (FSH) should be&#xD;
                  requested to confirm post-menopausal status. Post menopausal women confirmed by&#xD;
                  FSH level &gt; 40 mIU (milli-international units per milliliter) /mL, will be&#xD;
                  confirmed by central laboratory.&#xD;
&#xD;
               2. Women of childbearing potential (WOCBP) must have a negative pregnancy test at&#xD;
                  Screening and Baseline, and be willing to use highly effective methods of&#xD;
                  contraception from the Screening visit until 3 months after last dose of study&#xD;
                  drug. If re-test is required, a local urine pregnancy test will be performed at&#xD;
                  Baseline to determine if the subject can continue to randomisation.&#xD;
&#xD;
               3. Are permanently sterile or have had a hysterectomy, bilateral salpingectomy or&#xD;
                  bilateral oophorectomy.&#xD;
&#xD;
               4. Women must not be breastfeeding.&#xD;
&#xD;
          3. Male Subjects:&#xD;
&#xD;
               1. Who are sexually active, fertile men must use highly effective methods of&#xD;
                  contraception from Day 1 until 3 months after last dose of study drug if their&#xD;
                  partners are WOCBP.&#xD;
&#xD;
               2. Who are permanently sterile or have had bilateral orchiectomy.&#xD;
&#xD;
          4. Diagnosis of mild dementia due to Alzheimer's disease (AD) with increased level of&#xD;
             certainty (provided by evidence of clinical deterioration within the 6 months&#xD;
             preceding Screening, as assessed by the investigator) as determined by the National&#xD;
             Institute of Ageing (NIA) and the Alzheimer's Association (AA) workgroup.&#xD;
&#xD;
          5. Mild dementia due to probable AD with Mini-Mental Status Examination (MMSE) 20 to 26&#xD;
             (inclusive).&#xD;
&#xD;
          6. Clinical Dementia Rating Scale (CDR) Global Score of 0.5 to 1.0.&#xD;
&#xD;
          7. A brain magnetic resonance imaging (MRI) or computed tomography (CT) scan in the 12&#xD;
             months preceding Screening that in the investigator's opinion is consistent with AD as&#xD;
             the principle aetiology of the dementia with no other clinically significant&#xD;
             abnormality, e.g. another principle underlying aetiology of the subject's dementia, or&#xD;
             a lesion which could affect cognition e.g. a brain tumour or large stroke.&#xD;
&#xD;
          8. On stable dose of acetylcholinesterase (AChEI) and/or memantine (at least 3 months&#xD;
             prior to Screening) OR treatment-naïve. Initiating AChEIs or memantine during the&#xD;
             study will not be permitted.&#xD;
&#xD;
          9. Apart from a clinical diagnosis of mild dementia due to AD, the subject must be in&#xD;
             good health as determined by the investigator, based on medical history and screening&#xD;
             assessments.&#xD;
&#xD;
         10. Has a consenting study partner who, in the investigator's judgement, has frequent and&#xD;
             sufficient contact with the subject to be able to provide accurate information as to&#xD;
             the subject's cognitive and functional abilities. The study partner must be available&#xD;
             to provide information to the investigator and study site staff about the subject and&#xD;
             agrees to attend all study site visits in person for scale completion. A study partner&#xD;
             should be available for the duration of the study. The measure of adequate&#xD;
             availability will be at the investigator's discretion.&#xD;
&#xD;
         11. Must be willing and able to comply with the requirements of the protocol and must be&#xD;
             available to complete the study.&#xD;
&#xD;
         12. Must satisfy a medical examiner about their fitness to participate in the study.&#xD;
&#xD;
         13. Must provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormalities in vital signs (blood pressure, heart rate,&#xD;
             respiration rate and oral temperature), as determined by the investigator.&#xD;
&#xD;
          2. Clinically significant abnormal haematology, biochemistry and urine examination&#xD;
             values, specifically abnormal liver and renal function and Vitamin B12 levels below&#xD;
             lower threshold since these parameters may impact cognitive function, as determined by&#xD;
             the investigator.&#xD;
&#xD;
          3. Has had a significant systematic illness or infection within the past 4 weeks prior to&#xD;
             randomisation, as determined by the investigator.&#xD;
&#xD;
          4. Clinically significant neurological disease other than AD, such as (but not limited&#xD;
             to) Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure&#xD;
             hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder,&#xD;
             subdural haematoma, multiple sclerosis or a history of significant head trauma&#xD;
             followed by persistent neurologic defaults or known structural brain abnormalities.&#xD;
&#xD;
          5. Subjects with clinical evidence of peripheral neuropathy or historical evidence of&#xD;
             clinically significant nerve conduction abnormalities.&#xD;
&#xD;
          6. Has had a stroke within the year prior to randomisation, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          7. Has a lifetime diagnosis of a major psychiatric disorder (other than dementia), based&#xD;
             on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria.&#xD;
             This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar&#xD;
             affective disorder, alcohol dependence syndrome or major depressive disorder.&#xD;
&#xD;
          8. Has a history of disease directly related to the hypothalamus, the pituitary and/or&#xD;
             the adrenal glands which affect the hypothalamic-pituitary-adrenal axis function.&#xD;
&#xD;
          9. Has uncontrolled clinical conditions relating to glucose and lipid metabolism.&#xD;
&#xD;
         10. Clinically significant electrocardiogram (ECG) abnormalities, including Corrected QT&#xD;
             interval (QTc) &gt; 450 ms, following ECG tracings at Screening.&#xD;
&#xD;
         11. Use of any prohibited medication as detailed in the study protocol.&#xD;
&#xD;
         12. Participation in another clinical study of an investigational drug or device whereby&#xD;
             the last investigational drug/device administration is within 60 days of Screening.&#xD;
&#xD;
         13. Inability to communicate well with the investigator (i.e. language problem, non-fluent&#xD;
             English [as scales will be provided in English only], poor mental development or&#xD;
             impaired cerebral function).&#xD;
&#xD;
         14. Subject will undergo the tests, Alzheimer's Disease Assessment Scales (ADAS)-Cog v14,&#xD;
             CDR-Sum of Boxes (SOB), MMSE, Neuropsychological Test Battery (NTB; executive domain)&#xD;
             and RAVLT at the indicated time-points to avoid uncontrolled learning effects.&#xD;
             Subjects who need to perform these tests externally to and in parallel with this study&#xD;
             will be excluded.&#xD;
&#xD;
         15. Subject has ingested any food or drink containing grapefruit, Seville oranges, star&#xD;
             fruit or derived products (e.g. fruit juice), for at least 3 days prior to the first&#xD;
             administration of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bill Ketelbey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Actinogen Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Boyd, MD, FFPM</last_name>
    <role>Study Director</role>
    <affiliation>Actinogen Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tucson Neuroscience Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCND Neuroscience Research Institute</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Alliance Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC, Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroStudies.Net, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NeuroCognitive Institute</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>07856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Rocky Mount, LLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Neurosciences Research</name>
      <address>
        <city>Central Coast</city>
        <state>New South Wales</state>
        <zip>2261</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KaRa Institute of Neurological Diseases</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2113</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Alzheimer's Research Foundation</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute for the Care of Older People</name>
      <address>
        <city>Bath</city>
        <state>Combe Park</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Mental Health &amp; Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West London Mental Health Trust</name>
      <address>
        <city>Isleworth</city>
        <state>London</state>
        <zip>TW7 6FY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Pancras Clinical Research</name>
      <address>
        <city>Kings Cross</city>
        <state>London</state>
        <zip>WC1X 8QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Sciences, Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH8 9YL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1111/bph.13699</url>
    <description>Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1) inhibitor UE2343 (Xanamem™)</description>
  </link>
  <reference>
    <citation>Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25.</citation>
    <PMID>28012176</PMID>
  </reference>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>April 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2021</results_first_posted>
  <last_update_submitted>April 20, 2022</last_update_submitted>
  <last_update_submitted_qc>April 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Xanamem</keyword>
  <keyword>UE2343 (Laboratory Code for Xanamem)</keyword>
  <keyword>Cortisol</keyword>
  <keyword>XanADu</keyword>
  <keyword>Actinogen</keyword>
  <keyword>11β-HSD1</keyword>
  <keyword>11-beta-Hydroxysteroid Dehydrogenase Type 1</keyword>
  <keyword>Mild Alzheimer's Disease</keyword>
  <keyword>Cognitive Impairments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02727699/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02727699/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited based on physician referral between March 2017 to November 2018 when enrolment completed. This was a global, multi-center study involving 27 study sites, of which, 24 sites had randomised subjects to the study.The study planned to enrol 7 to 10 subjects at each study site.</recruitment_details>
      <pre_assignment_details>It was planned that approximately 174 subjects would be enrolled to ensure 156 subjects would complete the 12 week double-blind study period (78 subjects in each treatment group). At study-end, in total, 457 subjects were screened, of whom 185 subjects were randomised (91:94 Xanamem to placebo) to the study with 171 subjects completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xanamem™</title>
          <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343 (Laboratory code for Xanamem)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The FAS comprised all subjects randomised who received at least one dose of study drug and had at least one valid post-baseline measurement where changes from Baseline were analysed.&#xD;
Demographic data and subject characteristics at Baseline were summarised overall and by treatment, group using descriptive summary statistics for the Full Analysis Set (FAS) to include: age, gender and race. Baseline characteristic results of height, weight, BMI were also summarised overall and by treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Xanamem™</title>
          <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age was calculated as (informed consent year-birth year).</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="8.71"/>
                    <measurement group_id="B2" value="70.8" spread="8.20"/>
                    <measurement group_id="B3" value="71.0" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not available (NA)</measurement>
                    <measurement group_id="B2" value="NA">Data not available (NA)</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Subject Allocation By Study Sites by Country Region</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Number of subjects in the specified category with non-missing values in the Full Analysis Set (FAS).</population>
          <units>centimetres (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.49" spread="9.665"/>
                    <measurement group_id="B2" value="166.36" spread="8.964"/>
                    <measurement group_id="B3" value="165.94" spread="9.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>The overall mean (SD) Body Mass Index (BMI) of subjects was 27.19 (5.855) kg/m^2 and ranged from 17.9 kg/m^2 to 52.5 kg/m^2.</description>
          <population>Baseline value is defined as the latest observation prior to or on the date of the first dose of study drug.</population>
          <units>kilogram / square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.31" spread="5.024"/>
                    <measurement group_id="B2" value="27.08" spread="6.570"/>
                    <measurement group_id="B3" value="27.19" spread="5.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.90" spread="15.964"/>
                    <measurement group_id="B2" value="74.88" spread="18.774"/>
                    <measurement group_id="B3" value="74.89" spread="17.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ADAS-Cog v14</title>
        <description>Change in Alzheimer's Disease Assessment Scales - Cognitive Subscale Score, version 14 (ADAS-Cog v14) Total scores of ADAS Cog 14 range from 0 to 90, with higher scores indicating greater disease severity.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ADAS-cog v14 includes the following 14 items, with a Total scoring range of 0 - 90. Higher scores indicate greater disease severity</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>ADAS-Cog v14</title>
          <description>Change in Alzheimer's Disease Assessment Scales - Cognitive Subscale Score, version 14 (ADAS-Cog v14) Total scores of ADAS Cog 14 range from 0 to 90, with higher scores indicating greater disease severity.</description>
          <population>The ADAS-cog v14 includes the following 14 items, with a Total scoring range of 0 - 90. Higher scores indicate greater disease severity</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="6.47"/>
                    <measurement group_id="O2" value="-0.7" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AD COMposite Scores</title>
        <description>Change in AD COMposite Scores (ADCOMs- ADCOMs, composite score is derived from a weighted linear combination of items from commonly used outcome scales Cognitive Subscale Version 14 [ADAS-Cog v14], Clinical Dementia Rating Scale - Sum of Boxes [CDR-SOB], and Mini-Mental Status Examination [MMSE]. Th ADCOMs range: 0 - 1.97, whereas a lover score is interpreted as a better result.&#xD;
Included scales:&#xD;
ADAS-Cog v14 (range: 0-90): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
CDR-SOB (range: 0-18): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
MMSE (range: 0-30): A higher score is indicative of better cognition, a lower score indicates higher cognitive impairment.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ADCOMs, composite score (0 - 1.97) is derived from ADAS-Cog v14, CDR-SOB, and MMSE. Analysis of Change from Baseline to Week 12/end of treatment (EOT) in ADCOMs from the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>AD COMposite Scores</title>
          <description>Change in AD COMposite Scores (ADCOMs- ADCOMs, composite score is derived from a weighted linear combination of items from commonly used outcome scales Cognitive Subscale Version 14 [ADAS-Cog v14], Clinical Dementia Rating Scale - Sum of Boxes [CDR-SOB], and Mini-Mental Status Examination [MMSE]. Th ADCOMs range: 0 - 1.97, whereas a lover score is interpreted as a better result.&#xD;
Included scales:&#xD;
ADAS-Cog v14 (range: 0-90): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
CDR-SOB (range: 0-18): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.&#xD;
MMSE (range: 0-30): A higher score is indicative of better cognition, a lower score indicates higher cognitive impairment.</description>
          <population>ADCOMs, composite score (0 - 1.97) is derived from ADAS-Cog v14, CDR-SOB, and MMSE. Analysis of Change from Baseline to Week 12/end of treatment (EOT) in ADCOMs from the Full Analysis Set (FAS).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02472" spread="0.144135"/>
                    <measurement group_id="O2" value="0.01908" spread="0.151502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAVLT</title>
        <description>Change in Rey Auditory Verbal Learning Test (RAVLT) RAVLT will be administered using five trials, with individual scores from 0-15. The total score is the combined score of all five trials, ranging from 0 to 75, whereas a lower score is considered a worse outcome and a higher score a better outcome.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis of Change from Baseline to Week 12/EOT in RAVLT from the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>RAVLT</title>
          <description>Change in Rey Auditory Verbal Learning Test (RAVLT) RAVLT will be administered using five trials, with individual scores from 0-15. The total score is the combined score of all five trials, ranging from 0 to 75, whereas a lower score is considered a worse outcome and a higher score a better outcome.</description>
          <population>Analysis of Change from Baseline to Week 12/EOT in RAVLT from the Full Analysis Set (FAS).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recall List A - Total number of correct words</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.54"/>
                    <measurement group_id="O2" value="0.4" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recall List B - Number of correct words</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.63"/>
                    <measurement group_id="O2" value="0.1" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final recall of List A - Number of correct words</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.14"/>
                    <measurement group_id="O2" value="0.4" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDR-SOB</title>
        <description>Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB) The CDR is obtained through semi-structured interviews of patients and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.&#xD;
Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment.&#xD;
The CDR-SOB is based on summing each of the domain box scores, with scores ranging from 0-18, whereas lower scores represent better outcomes and higher scores worse outcomes.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>CDR-SOB score (0 - 18) is a sum of all six items of CDR-SOB. CDR-SOB score will be analysed for each visit as actual values and change from Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>CDR-SOB</title>
          <description>Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB) The CDR is obtained through semi-structured interviews of patients and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.&#xD;
Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment.&#xD;
The CDR-SOB is based on summing each of the domain box scores, with scores ranging from 0-18, whereas lower scores represent better outcomes and higher scores worse outcomes.</description>
          <population>CDR-SOB score (0 - 18) is a sum of all six items of CDR-SOB. CDR-SOB score will be analysed for each visit as actual values and change from Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="1.276"/>
                    <measurement group_id="O2" value="0.16" spread="1.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MMSE</title>
        <description>Change in Mini-Mental Status Examination (MMSE) MMSE total score (0 - 30) is a sum of all 30 point questionnaire of MMSE. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>MMSE is a 30 point questionnaire used to screen for dementia and to estimate the severity and progression of cognitive impairment. MMSE will be analysed for each visit as actual values and change from Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>MMSE</title>
          <description>Change in Mini-Mental Status Examination (MMSE) MMSE total score (0 - 30) is a sum of all 30 point questionnaire of MMSE. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
          <population>MMSE is a 30 point questionnaire used to screen for dementia and to estimate the severity and progression of cognitive impairment. MMSE will be analysed for each visit as actual values and change from Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.09"/>
                    <measurement group_id="O2" value="-0.2" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NPI (Neuropsychiatric Inventory)</title>
        <description>Change in Neuropsychiatric Inventory (NPI) The NPI includes questions to ten behavioural and two neurodegenerative domains.&#xD;
Raters recorded neuropsychiatric symptoms using a 1-4 scale for frequency and a 1-3 scale for severity for each item in the instrument, with the score for each domain being: domain score = frequency x severity.&#xD;
The total score is calculated by adding the scores of the first 10 domain scores.&#xD;
The two neurodegenerative items are not included in the NPI total score as they form part of the depression syndrome in some patients and were specifically excluded from the dysphoria subscale of the NPI in order to allow that subscale to focus on mood symptoms.&#xD;
The total NPI-score minimum is 0 and the maximum 144. A lower score is considered a better outcome, a higher score a worse outcome.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The NPI total score is calculated by multiplying the frequency and severity rates per domain (maximum score per domain is 12) and then calculating the total of all domains (total NPI-score minimum is 0 and maximum 144). Total distress score (0 - 60) will summarised descriptively. NPI total score will not be calculated if any sub item is missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>NPI (Neuropsychiatric Inventory)</title>
          <description>Change in Neuropsychiatric Inventory (NPI) The NPI includes questions to ten behavioural and two neurodegenerative domains.&#xD;
Raters recorded neuropsychiatric symptoms using a 1-4 scale for frequency and a 1-3 scale for severity for each item in the instrument, with the score for each domain being: domain score = frequency x severity.&#xD;
The total score is calculated by adding the scores of the first 10 domain scores.&#xD;
The two neurodegenerative items are not included in the NPI total score as they form part of the depression syndrome in some patients and were specifically excluded from the dysphoria subscale of the NPI in order to allow that subscale to focus on mood symptoms.&#xD;
The total NPI-score minimum is 0 and the maximum 144. A lower score is considered a better outcome, a higher score a worse outcome.</description>
          <population>The NPI total score is calculated by multiplying the frequency and severity rates per domain (maximum score per domain is 12) and then calculating the total of all domains (total NPI-score minimum is 0 and maximum 144). Total distress score (0 - 60) will summarised descriptively. NPI total score will not be calculated if any sub item is missing.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NPI Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="8.67"/>
                    <measurement group_id="O2" value="0.8" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.38"/>
                    <measurement group_id="O2" value="0.1" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.60"/>
                    <measurement group_id="O2" value="0.0" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation/Aggression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.02"/>
                    <measurement group_id="O2" value="0.2" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression/Dysphoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.34"/>
                    <measurement group_id="O2" value="0.0" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.70"/>
                    <measurement group_id="O2" value="-0.4" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elation/Euphoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.92"/>
                    <measurement group_id="O2" value="0.0" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apathy/Indifference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.18"/>
                    <measurement group_id="O2" value="0.3" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disinhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.15"/>
                    <measurement group_id="O2" value="0.1" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Lability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.94"/>
                    <measurement group_id="O2" value="0.5" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aberrant Motor Behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.98"/>
                    <measurement group_id="O2" value="0.2" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.47"/>
                    <measurement group_id="O2" value="0.0" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite and Eating Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.18"/>
                    <measurement group_id="O2" value="-0.1" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NTB - Executive Domain</title>
        <description>Change in Neuropsychological Test Batteries (NTB) - Executive Domains: Controlled Oral Word Association - Test (COWAT) and Total Correct Response (CFT) Total NTB score is the sum of COWAT and CFT. During the COWAT test, the subject is asked to mention as many words as possible beginning with different letters (F, A, S) within 1 minute each. The number of words for each letter is recorded, the score is the sum of all words. There is no minimum or maximum score, whereas more words indicate a better outcome.&#xD;
During the CFT test, the subject is given 1 minute to produce as many unique words as possible within a semantic category. The subject's score is the number of unique correct words.&#xD;
There is no minimum or maximum score whereas a score of under 14 is interpreted as concerning regarding cognition.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Total NTB score is the sum of 'Total correct response' of Category Fluency Test (CFT) and 'Total number of correct words' of Controlled Oral Word Association Test (COWAT). Each score ('Total correct response' of CFT and 'Total number of correct word' of COWAT) will also be analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Xanamem™</title>
            <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
          </group>
        </group_list>
        <measure>
          <title>NTB - Executive Domain</title>
          <description>Change in Neuropsychological Test Batteries (NTB) - Executive Domains: Controlled Oral Word Association - Test (COWAT) and Total Correct Response (CFT) Total NTB score is the sum of COWAT and CFT. During the COWAT test, the subject is asked to mention as many words as possible beginning with different letters (F, A, S) within 1 minute each. The number of words for each letter is recorded, the score is the sum of all words. There is no minimum or maximum score, whereas more words indicate a better outcome.&#xD;
During the CFT test, the subject is given 1 minute to produce as many unique words as possible within a semantic category. The subject's score is the number of unique correct words.&#xD;
There is no minimum or maximum score whereas a score of under 14 is interpreted as concerning regarding cognition.</description>
          <population>Total NTB score is the sum of 'Total correct response' of Category Fluency Test (CFT) and 'Total number of correct words' of Controlled Oral Word Association Test (COWAT). Each score ('Total correct response' of CFT and 'Total number of correct word' of COWAT) will also be analysed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>COWAT Total Correct Words</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="8.08"/>
                    <measurement group_id="O2" value="0.5" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTF Total Correct Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="8.53"/>
                    <measurement group_id="O2" value="-0.7" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTB Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="11.50"/>
                    <measurement group_id="O2" value="-0.2" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pregnancy Test</title>
        <description>Women of childbearing potential only. Serum pregnancy test at screening and a urine pregnancy test at all subsequent clinic visits</description>
        <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Testosterone</title>
        <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
        <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Androstenedione</title>
        <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
        <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Dehydroepiandrosterone Sulfate (DHEAS)</title>
        <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
        <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Adrenocorticotropic Hormone (ACTH)</title>
        <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
        <time_frame>Screening, baseline, Week 4, Week, 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Pharmacokinetics (PK), Including Analysis of Cortisol Levels</title>
        <description>This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit</description>
        <time_frame>Baseline, Week 4, Week 8, Week 12 and Unscheduled Safety Visit</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NTSS-6</title>
        <description>Change in Neuropathy Total Symptom Score (NTSS-6)</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc and Unscheduled Safety Visit</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NFM</title>
        <description>Change in Nerve Function Monitoring (NFM)</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs</title>
        <description>Change in Vital Signs (including Heart Rate, Blood Pressure, Body Weight, BMI)</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Unscheduled Safety Visit</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metabolic Function</title>
        <description>Change in Metabolic Function Test Results of Lipids, Glucose, Hemoglobin A1c (HbA1c)</description>
        <time_frame>Baseline, Week 12</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Safety Laboratory Values</title>
        <description>Change in Clinical Safety Laboratory Values (biochemistry, hematology, urine examination)</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>AEs</title>
        <description>Incidence of Adverse Events (AEs)</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ECG</title>
        <description>Change in Electrocardiogram (ECG) Values</description>
        <time_frame>Screening, Baseline, Week 4, Week 8, Week 12, Week 16</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CSSRS</title>
        <description>Change in Scores of Columbia Suicide Severity Rating Scale (CSSRS)</description>
        <time_frame>Screening, Week 4, Week 8, Week 12, Week 16</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Median treatment duration (weeks) was 12 weeks (range: 0.14, 13.0 weeks) for subjects in the Xanamem group and 12 weeks (range: 0.14, 13.1 weeks) for subjects in the placebo group.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xanamem™</title>
          <description>Oral Xanamem™ capsules 10mg, to be administered once daily&#xD;
Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily&#xD;
Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vibration test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Cavitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Drug Development &amp; Strategy</name_or_title>
      <organization>Actinogen Medical Limited</organization>
      <phone>+61289647401</phone>
      <email>info@actinogen.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

